Turning Obstacles Into Opportunities: Overcoming Efficiency And Quality Challenges In Gene Therapy Development

By Dr. Ger Brophy, Chair of the Avantor Scientific Advisory Board

Despite rapid advancements and increased regulatory support, scaling up gene therapy production remains a critical hurdle as inefficiencies, such as inconsistent vector yields and quality, persist. This article highlights the importance of collaboration and innovation in addressing these issues, from adopting new cell lines to integrating artificial intelligence in process optimization. As gene therapy moves beyond rare diseases to more complex conditions, ensuring manufacturing efficiency, standardization, and quality is key to reaching larger patient populations.